Latest Insider Transactions at I Teos Therapeutics, Inc. (ITOS)
This section provides a real-time view of insider transactions for I Teos Therapeutics, Inc. (ITOS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of iTeos Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of iTeos Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 06
2024
|
David Feltquate Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,000
+50.0%
|
-
|
|
Nov 19
2024
|
Matthew Gall Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+7.1%
|
$35,000
$7.73 P/Share
|
|
May 12
2024
|
Ra Capital Management, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
900,000
-26.12%
|
-
|
|
May 10
2024
|
Boxer Capital, LLC |
BUY
Grant, award, or other acquisition
|
Direct |
1,142,857
+27.94%
|
$19,428,569
$17.5 P/Share
|
|
Dec 05
2023
|
Michel Detheux Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+33.74%
|
-
|
|
Dec 05
2023
|
Matthew Gall Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+40.42%
|
-
|
|
Dec 05
2023
|
Matthew Call Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+24.19%
|
-
|
|
Dec 05
2023
|
Yvonne Mc Grath Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,000
+50.0%
|
-
|
|
Oct 12
2023
|
Matthew Gall Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+20.47%
|
$40,000
$8.37 P/Share
|
|
Aug 23
2023
|
Boxer Capital, LLC |
SELL
Open market or private sale
|
Direct |
350,000
-5.66%
|
$5,250,000
$15.56 P/Share
|
|
Mar 28
2023
|
Matthew Call Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,226
+29.99%
|
$80,452
$2.95 P/Share
|
|
Jun 09
2022
|
David Hallal |
SELL
Open market or private sale
|
Direct |
1,171
-100.0%
|
$22,249
$19.51 P/Share
|
|
Jun 09
2022
|
David Hallal |
BUY
Exercise of conversion of derivative security
|
Direct |
1,171
+50.0%
|
$4,684
$4.23 P/Share
|
|
Jun 08
2022
|
David Hallal |
SELL
Open market or private sale
|
Direct |
28,444
-100.0%
|
$568,880
$20.21 P/Share
|
|
Jun 08
2022
|
David Hallal |
BUY
Exercise of conversion of derivative security
|
Direct |
28,444
+50.0%
|
$85,332
$3.8 P/Share
|
|
May 11
2022
|
Aaron I. Davis |
SELL
Open market or private sale
|
Indirect |
338,000
-6.78%
|
$5,746,000
$17.89 P/Share
|
|
May 10
2022
|
Aaron I. Davis |
SELL
Open market or private sale
|
Indirect |
100,000
-1.93%
|
$2,400,000
$24.98 P/Share
|
|
May 09
2022
|
Aaron I. Davis |
SELL
Open market or private sale
|
Indirect |
225,000
-4.03%
|
$5,175,000
$23.19 P/Share
|
|
May 02
2022
|
Aaron I. Davis |
SELL
Open market or private sale
|
Indirect |
100,000
-1.72%
|
$2,700,000
$27.22 P/Share
|
|
Apr 29
2022
|
Aaron I. Davis |
SELL
Open market or private sale
|
Indirect |
125,000
-2.06%
|
$3,375,000
$27.62 P/Share
|
|
Apr 28
2022
|
Aaron I. Davis |
SELL
Open market or private sale
|
Indirect |
150,000
-4.7%
|
$4,050,000
$27.4 P/Share
|
|
Apr 18
2022
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,500
-15.25%
|
$368,000
$32.26 P/Share
|
|
Apr 18
2022
|
Michel Detheux Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,500
+23.34%
|
$46,000
$4.23 P/Share
|
|
Mar 23
2022
|
Aaron I. Davis |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.62%
|
$640,000
$32.85 P/Share
|
|
Mar 22
2022
|
Aaron I. Davis |
BUY
Open market or private purchase
|
Indirect |
30,000
+0.31%
|
$960,000
$32.8 P/Share
|
|
Mar 22
2022
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,437
-12.02%
|
$626,858
$34.82 P/Share
|
|
Mar 17
2022
|
Boxer Capital, LLC |
SELL
Open market or private sale
|
Direct |
575,201
-15.47%
|
$20,132,035
$35.25 P/Share
|
|
Mar 11
2022
|
Michel Detheux Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+18.28%
|
-
|
|
Mar 11
2022
|
Joanne Jenkins Lager Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,500
-100.0%
|
$126,000
$36.01 P/Share
|
|
Mar 11
2022
|
Joanne Jenkins Lager Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+50.0%
|
$14,000
$4.3 P/Share
|
|
Mar 01
2022
|
Yvonne Mc Grath Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$360,000
$36.76 P/Share
|
|
Mar 01
2022
|
Yvonne Mc Grath Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$40,000
$4.24 P/Share
|
|
Feb 23
2022
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,500
-14.95%
|
$493,000
$34.81 P/Share
|
|
Feb 11
2022
|
Joanne Jenkins Lager Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,500
-78.31%
|
$122,500
$35.9 P/Share
|
|
Feb 11
2022
|
Joanne Jenkins Lager Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+50.0%
|
$14,000
$4.3 P/Share
|
|
Jan 25
2022
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,500
-12.03%
|
$507,500
$35.83 P/Share
|
|
Jan 14
2022
|
Joanne Jenkins Lager Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,500
-89.67%
|
$136,500
$39.42 P/Share
|
|
Jan 14
2022
|
Joanne Jenkins Lager Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+50.0%
|
$14,000
$4.3 P/Share
|
|
Jan 05
2022
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
18,135
-0.66%
|
$761,670
$42.03 P/Share
|
|
Jan 05
2022
|
Mpm Bioventures 2018, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
18,135
-0.66%
|
$761,670
$42.03 P/Share
|
|
Jan 05
2022
|
Ansbert Gadicke > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,347
-0.67%
|
$1,274,574
$42.03 P/Share
|
|
Jan 04
2022
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
128,550
-1.12%
|
$5,656,200
$44.26 P/Share
|
|
Jan 04
2022
|
Mpm Bioventures 2018, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
128,550
-1.12%
|
$5,656,200
$44.26 P/Share
|
|
Jan 04
2022
|
Ansbert Gadicke > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
215,122
-1.15%
|
$9,465,368
$44.26 P/Share
|
|
Jan 04
2022
|
Boxer Capital, LLC |
SELL
Open market or private sale
|
Direct |
184,677
-33.45%
|
$7,941,111
$43.78 P/Share
|
|
Jan 03
2022
|
Boxer Capital, LLC |
SELL
Open market or private sale
|
Direct |
515,323
-8.12%
|
$25,250,827
$49.21 P/Share
|
|
Jan 03
2022
|
Detlev Biniszkiewicz Director |
SELL
Open market or private sale
|
Direct |
3,500
-100.0%
|
$178,500
$51.9 P/Share
|
|
Jan 03
2022
|
Detlev Biniszkiewicz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+50.0%
|
$66,500
$19.0 P/Share
|
|
Jan 03
2022
|
Joanne Jenkins Lager Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$357,000
$51.9 P/Share
|
|
Jan 03
2022
|
Joanne Jenkins Lager Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$28,000
$4.3 P/Share
|